| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.88 [0.77, 1.01] | | < 1 | | 34% | 3 studies (3/-) | 96.1 % | low | not evaluable | high | crucial | - |
| progression or deaths (PFS) | 0.96 [0.57, 1.61] | | < 1 | | 95% | 3 studies (3/-) | 56.2 % | low | not evaluable | high | important | - |
| DCR | 0.60 [0.39, 0.94] | | > 1 | | 0% | 1 study (1/-) | 1.3 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.69 [0.20, 2.40] | | > 1 | | 96% | 3 studies (3/-) | 28.2 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.25 [0.41, 3.87] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.26 [0.91, 1.76] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 0.99 [0.66, 1.48] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 1.35 [0.68, 2.70] | | < 1 | | 0% | 1 study (1/-) | 19.7 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.56 [0.16, 1.99] | | < 1 | | 96% | 2 studies (2/-) | 81.6 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.00 [0.41, 2.47] | | < 1 | | 0% | 2 studies (2/-) | 49.6 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.05 [0.42, 2.63] | | < 1 | | 0% | 1 study (1/-) | 45.7 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.84 [0.22, 3.26] | | < 1 | | 0% | 2 studies (2/-) | 59.7 % | low | not evaluable | high | non important | - |
| Anaemia TRAE (grade 3-4) | 0.65 [0.17, 2.54] | | < 1 | | 76% | 2 studies (2/-) | 73.3 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 1.26 [0.28, 5.69] | | < 1 | | 0% | 1 study (1/-) | 38.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 1.04 [0.10, 10.27] | | < 1 | | 0% | 2 studies (2/-) | 48.7 % | low | not evaluable | high | non important | - |
| Constipation TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.23 [0.05, 1.10] | | < 1 | | 0% | 1 study (1/-) | 96.7 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.10 [0.50, 2.40] | | < 1 | | 0% | 2 studies (2/-) | 41.0 % | low | not evaluable | high | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.79] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.98 [0.07, 12.73] | | < 1 | | 0% | 2 studies (2/-) | 50.7 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.95 [0.20, 19.31] | | < 1 | | 0% | 2 studies (2/-) | 28.5 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 1.91 [0.57, 6.42] | | < 1 | | 0% | 1 study (1/-) | 14.7 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.32 [0.70, 2.49] | | < 1 | | 0% | 2 studies (2/-) | 19.5 % | low | not evaluable | high | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.46 [0.07, 3.09] | | < 1 | | 53% | 2 studies (2/-) | 78.8 % | low | not evaluable | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 5.72 [0.29, 114.60] | | < 1 | | 0% | 1 study (1/-) | 13.0 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 1.03 [0.33, 3.14] | | < 1 | | 0% | 2 studies (2/-) | 48.3 % | low | not evaluable | high | non important | - |
| Nephritis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.11 [0.00, 12.49] | | < 1 | | 91% | 2 studies (2/-) | 81.5 % | low | not evaluable | high | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.13 [0.02, 1.08] | | < 1 | | 0% | 1 study (1/-) | 97.0 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 0.16 [0.01, 3.13] | | < 1 | | 0% | 1 study (1/-) | 88.5 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 0.24 [0.01, 5.23] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 5.89 [0.74, 47.15] | | < 1 | | 0% | 2 studies (2/-) | 4.8 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 3.82 [0.61, 23.97] | | < 1 | | 0% | 2 studies (2/-) | 7.7 % | some concern | not evaluable | moderate | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.47 [0.02, 14.11] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.94 [0.06, 15.18] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.94 [0.02, 47.78] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Urticaria TRAE (grade 3-4) | 1.89 [0.06, 56.64] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.47 [0.04, 5.22] | | < 1 | | 0% | 1 study (1/-) | 72.9 % | NA | not evaluable | | non important | - |
